You are here: Industry Insights > BioVaxys

News List

Biovaxys And The World Ovarian Cancer Coalition Join Forces For May 8th, World Ovarian Cancer Day prnasia
April 21, 2021
BioVaxys Technology Corp., the world leader in haptenized antigen vaccines for antiviral and cancers applications, announced today its sponsorship of this year's World Ovarian Cancer Day, a major initiative of the World Ovarian Cancer Coalition, an ...
BioVaxys Announces Final Clinical trial results of HPV product from EU partner ProCare Health Iberia published by American Society for Colposcopy and Cervical Pathology prnasia
April 15, 2021
BioVaxys Technology Corp., the world leader in haptenized antigen vaccines for antiviral and cancers applications, is pleased to announce the results of a clinical study conducted by ProCare Health Iberia, its EU partner for marketing its ...
BIOVAXYS files FDA pre-IND meeting request and briefing package for COVID-T prnasia
March 31, 2021
BioVaxys Technology Corp., the world leader in haptenized antigen vaccines for antiviral and cancer applications, announced today that it is has filed a pre-IND (Investigational New Drug) meeting request and submitted a briefing package with the ...
BioVaxys Enters Agreement With Inotiv To Conduct Preclinical Toxicity Studies For Its Covid-T™ Immunodiagnostic Program prnewswire
March 19, 2021
BioVaxys Technology Corp., the world leader in haptenized protein vaccines for antiviral and cancer applications, announced that it has entered into an agreement with Bioanalytical Systems, Inc. d/b/a Inotiv, a global Contract Research Organization ...
BioVaxys, Wuxi Biologics Enter Bioproduction Agreement contractpharma
March 16, 2021
BioVaxys Technology, a provider of haptenized protein vaccines for antiviral and cancer applications, has entered into a major bioproduction agreement with WuXi Biologics, a global contract development and manufacturing organization (CDMO) and ...
BioVaxys and BioElpida Sign Term Sheet for Clinical Grade BVX-0918A Bio-production prnasia
February 19, 2021
BioVaxys Technology Corp. announced that it has signed a Term Sheet with BioElpida S.A.S. of Lyon, France, to collaborate on the build-out for the clinical-grade manufacturing process and aseptic packaging for BXV-0918A, BioVaxys' vaccine for Stage ...
BioVaxys Announces Initiation Of Cancer Vaccine EU Clinical Program, Completion Of BVX-0320 Preclinical Program prnasia
January 26, 2021
BioVaxys Technology Corp. is pleased to provide a corporate update on recent advancements of its vaccine platforms, and viral diagnostic and corporate objectives for 2021.
BioVaxys Vaccine Platform Stimulates Robust T-cell Response Against Viral Antigens prnasia
December 23, 2020
BioVaxys Technology Corp. announced that further analysis of the data from a preclinical animal study (also known as the "murine model study") of its haptenized viral protein vaccine technology show that BVX-0320, its COVID-19 vaccine candidate based ...

Previous page 1 2 Next page